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See related research by Gando et al., http://ccforum.com/content/17/3/R111We read with interest the recent issue of Critical Care,
particularly the article by Gando and colleagues [1] about
the validation of the scoring systems for disseminated
intravascular coagulation (DIC). Mortality in patients
with DIC according to diagnostic criteria of the Japanese
Association of Acute Medicine (JAAM; 31.8%) was similar
to that in patients with International Society of Thrombosis
and Haemostasis (ISTH) overt-DIC (30.1%). A previous
report [2] showed different results; mortality was signifi-
cantly higher in patients with overt-DIC (34.4%) than in
those with JAAM DIC (17.2%). The difference in the
mortality between this report [1] and the previous report
[2] may depend on not only the sensitivity of the diagnostic
criteria, but also on the antithrombotic therapy (ATT).* Correspondence: wadahide@clin.medic.mie-u.ac.jp
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2014Although most patients were considered to be treated
with ATT at the early stage of DIC in this study [1], those
treated in the other study [2] had late stage DIC [3]. As the
presence of neutrophil extracellular traps [4] and hyper-
coagulation in DIC induce localization of infection, the
administration of ATT may spread the infection. Therefore,
ATT may worsen sepsis in the early stage of the disease
while improving hemostatic abnormalities following organ
failure in patients with severe sepsis. Overall, ATT may not
improve the outcomes of patients with sepsis in the early
stage, although it can potentially improve the outcomes of
those with overt-DIC (Figure 1). The timing of ATT may
be too early in septic patients when using the JAAM diag-
nostic criteria and too late in those with ISTH overt-DIC.We appreciate the interest of Wada and colleagues in
our recently published article studying the JAAM DIC
scoring system in patients with severe sepsis [1]. It is now
widely accepted that localized platelet and fibrin throm-
bosis at the site of infection is a physiologic reaction that
protects against dissemination of microorganisms and
pathogen-associated molecular patterns derived from
them into the systemic circulation, which is now called
immunothrombosis [5]. Therefore, we agree that early
anticoagulation therapy for sepsis probably induces un-
controlled immunothrombosis, leading to pathological
systemic DIC. Fourrier [6] clearly demonstrated that the
target for the treatment of sepsis is not sepsis itself, but
DIC as a result of the overwhelming effects of sepsis onimmunothrombosis. The mortality rate of the severe
sepsis patients who met the JAAM DIC criteria was
31.8%, and the Kaplan-Meier curves clearly demon-
strated that there was a lower 1-year survival rate in the
JAAM DIC patients, which supports our opinion that the
DIC patients diagnosed by the JAAM scoring system
should be treated as early as possible [1]. The differences
in the mortality rate between the two studies pointed out
by Wada and colleagues were due to differences in the
subjects included in the two studies [1,2]. Our previous
study included diverse clinical conditions that were
associated with DIC [2], but the inclusion criteria for the
current study were restricted to only severe sepsis
patients [1].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Mortality due to sepsis and/or disseminated intravascular
coagulation (DIC). Open circles indicate without DIC treatment, closed
circles with DIC treatment.
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